Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
FDA-2015-N-3469-0001Notice
Comments
51
Last activity May 11, 2026
Deadline
8603 days
Closes Feb 22, 2050
Net supportiSupport minus oppose · campaigns included
+6%
+6% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
- Posted
- Oct 27, 2015
- Comment period
- Oct 27, 2015 – Feb 22, 2050
- FR Doc
- 2015-27270
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+6%
Net support
Support26Oppose23
Aggregates include form-letter campaigns. Excluding them, net support is +6% across organic comments.
Who commented
Breakdown by commenter type.
Academic
1
Business
25
Government
1
Individual
13
Trade association
5
Advocacy
4
Comments over time
Weekly arrivals, stacked by stance.
Posted Oct 27, 2015Deadline Feb 22, 2050
Dec 7Jun 18Jan 14Jul 5Dec 4Mar 17Nov 10May 11
Support26Oppose23Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Business
36%
64%
0%
Individual
69%
31%
0%
Trade association
100%
0%
0%
Advocacy
50%
50%
0%
Academic
100%
0%
0%
Government
0%
100%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Clinical need interpretation11
Compounded weight loss medications7
Compounded peptide access5
Bulk api use for 503b2
Nomination of succinylcholine chloride2
Compounding of thymosin alpha-11
Inclusion of inactive ingredients1
Mitomycin compounding safety1
Nomination of alpha lipoic acid1
Nomination of ashwagandha root extract1
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Bulk api use for 503b | Clinical need interpretation | Compounded weight loss medications | Mitomycin compounding safety | Nomination of alpha lipoic acid |
|---|
17 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.